CD200

CD200 Molekülinformation

Englischer Name	OX-2 membrane glycoprotein	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1	Target-Alias	My033，CD200，CD200 Antigen，Antigen Identified By Monoclonal Antibody MRC OX-2，MOX1，OX-2 Membrane Glycoprotein，OX-2，MRC，CD200 Molecule，MOX2
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	OX-2 membrane glycoprotein
Target-Alias	My033，CD200，CD200 Antigen，Antigen Identified By Monoclonal Antibody MRC OX-2，MOX1，OX-2 Membrane Glycoprotein，OX-2，MRC，CD200 Molecule，MOX2
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

CD200 Produktliste

Attribut
Protein (4)
Produktbibliothek
Online (4)
Spezies
Human (3)Mouse (1)
Etikett
Fc Tag (1)His Tag (1)Fc Tag & Avi Tag (2)
Marker
Unconjugated (2)Biotin-labeled (2)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
OX2-H5228	Human	HEK293	Human CD200 / OX-2 Protein, His Tag, low endotoxin	In den Warenkorb legen
OX2-H5251	Human	HEK293	Human CD200 / OX-2 Protein, Fc Tag, low endotoxin	In den Warenkorb legen
OX2-H82F1	Human	HEK293	Biotinylated Human CD200 / OX-2 Protein, Fc,Avitag™	In den Warenkorb legen
OX2-M82F3	Mouse	HEK293	Biotinylated Mouse CD200 / OX-2 Protein, Fc,Avitag™ (MALS verified)	In den Warenkorb legen

Gesamtmenge4

CD200 Molekülhintergrund

CD200 is also known as OX-2 membrane glycoprotein (OX-2), is a type-1 membrane glycoprotein, which contains two immunoglobulin domains (1 Ig-like C2-type (immunoglobulin-like) domain and Ig-like V-type (immunoglobulin-like) domain), and thus belongs to the immunoglobulin superfamily. CD200 / OX-2 is widely expressed in multiple cell types. CD200 interacts with a structurally related receptor (CD200R) expressed mainly on myeloid cells and is involved in regulation of macrophage and mast cell function. OX-2 / CD200 and CD200R associate via their respective N-terminal Ig-like domains. CD200 also plays an important role in prevention of graft rejection, autoimmune diseases and spontaneous abortion.

CD200 Molekülalias

CD200,MOX1,MOX2,MRC,OX-2,My033

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
P-006	23ME-00610; P-006; 23ME’610	Phase 2 Clinical	23andme Inc	Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Fallopian Tube Neoplasms; Microsatellite instability-high cancer; Neuroendocrine Tumors; Peritoneal Neoplasms; Small Cell Lung Carcinoma; Solid tumours	Details